申请人:Genfit
公开号:EP2641596A1
公开(公告)日:2013-09-25
The invention provides 1,3-diphenylprop-2-en-1-one derivatives and pharmaceutical compositions comprising the same for treating liver disorders, in particular those requiring the reduction of plasma level of biochemical markers such as aminotransferases . The 1,3-diphenylprop-2-en-1-one derivatives of General Formula (I) have hepatoprotective properties and can be used in methods for treating liver disorders involving the pathological disruption, inflammation, degeneration, and/or proliferation of liver cells, such as liver fibrosis or fatty liver disease.
本发明提供了 1,3-二苯基丙-2-烯-1-酮衍生物和包含 1,3-二苯基丙-2-烯-1-酮衍生物的药物组合物,用于治疗肝脏疾病,特别是需要降低血浆中转氨酶等生化指标水平的疾病。通式(I)的1,3-二苯基丙-2-烯-1-酮衍生物具有保肝特性,可用于治疗涉及肝细胞病理破坏、炎症、变性和/或增殖的肝脏疾病,如肝纤维化或脂肪肝。